esreboxetine has been researched along with atomoxetine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aparicio, A; Dwight, W; Eccles, W; Fleck, BA; Genicot, MJ; Gogas, K; Hudson, S; Kiankarimi, M; Mostofi, YS; Wade, WS; Wang, H; Wen, J | 1 |
| Bray, J; Deecher, D; Fensome, A; Harrison, J; Kim, C; Koury, E; Mahaney, PE; Mark, L; McComas, CC; Mugford, CA; Terefenko, EA; Trybulski, EJ; Vu, AT; Whiteside, GT; Zhang, P | 1 |
2 other study(ies) available for esreboxetine and atomoxetine
| Article | Year |
|---|---|
Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Chemistry, Pharmaceutical; Cytochrome P-450 CYP2D6; Drug Design; Humans; Inhibitory Concentration 50; Models, Chemical; Molecular Conformation; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxygen; Propylamines; Structure-Activity Relationship; Symporters | 2008 |
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
Topics: Administration, Oral; Animals; Behavior, Animal; Benzimidazoles; Biological Transport; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Hyperalgesia; Male; Neurotransmitter Uptake Inhibitors; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Propanolamines; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Spinal Nerves; Structure-Activity Relationship; Substrate Specificity | 2009 |